Global Pharmacogenetic Testing Market by Test Type (Single-Gene Testing, Panel Testing, Whole Genome Sequencing), by Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Microarray Technology, Others), by Application (Drug Response Assessment, Disease Risk Prediction, Personalized Medicine), by End-Use Industry (Hospitals and Clinics, Diagnostic Laboratories, Research Institutions, Pharmaceutical and Biotech Companies); Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Pharmacogenetic Testing Market was valued at USD 6.0 Billion in 2024-e and will surpass USD 10.6 Billion by 2030; growing at a CAGR of 10.0% during 2025 - 2030.

 The pharmacogenetic testing market is experiencing rapid growth, driven by the increasing focus on personalized medicine and the ability to tailor drug therapies based on genetic makeup. These tests help healthcare providers understand how genetic factors influence an individual’s response to drugs, thereby improving the efficacy and safety of treatments. The market is expanding as technological advancements enable more precise, accessible, and affordable genetic testing, allowing for broader applications across healthcare sectors.

Whole Genome Sequencing is Fastest Growing Owing to Expanding Clinical Applications

Whole genome sequencing (WGS) is the fastest-growing test type in the pharmacogenetic testing market, owing to its comprehensive nature and growing clinical applications. Unlike single-gene testing or panel testing, WGS analyzes the entire genome, offering a holistic view of an individual’s genetic profile. This capability allows for a more complete understanding of genetic predispositions, potential drug interactions, and personalized therapeutic options.

The application of WGS in drug response assessment and disease risk prediction is fueling its adoption across research institutions, diagnostic laboratories, and clinical settings. As the cost of sequencing continues to decline and bioinformatics tools improve, WGS is becoming increasingly viable for routine clinical use, driving its rapid growth in pharmacogenetics.

Drug Response Assessment Leads Applications Due to Its Role in Optimizing Treatment

Drug response assessment is the leading application of pharmacogenetic testing, as it plays a crucial role in optimizing drug therapies for individual patients. By understanding how a patient’s genetic makeup affects their response to specific medications, clinicians can avoid adverse drug reactions, improve therapeutic outcomes, and reduce treatment costs.

The growing prevalence of chronic diseases, cancer, and cardiovascular conditions has further driven the demand for personalized treatments. Pharmacogenetic tests can help identify the most effective drug for a patient, minimizing trial-and-error prescribing and enhancing patient satisfaction with treatment regimens.

Hospitals and Clinics Are Largest End-Use Industry Owing to Widespread Adoption

Hospitals and clinics represent the largest end-use industry in the pharmacogenetic testing market, driven by the increasing adoption of personalized medicine in clinical practice. Healthcare providers are increasingly incorporating pharmacogenetic testing into patient care to ensure more precise and effective treatments.

The integration of pharmacogenetic testing into routine clinical workflows, especially for oncology, cardiology, and psychiatry, is enhancing its growth. Healthcare systems are recognizing the potential benefits of pharmacogenetic testing in improving patient outcomes and reducing adverse drug events, making hospitals and clinics the largest consumers of these services.

North America Leads the Market Due to Advanced Healthcare Infrastructure and Research

North America holds the largest market share in the pharmacogenetic testing market, owing to its advanced healthcare infrastructure, high adoption rates of precision medicine, and strong research base. The U.S., in particular, is a major driver, with numerous leading biotechnology firms, research institutions, and healthcare providers at the forefront of pharmacogenetic testing innovation.

Government initiatives, insurance coverage for pharmacogenetic testing, and a strong emphasis on personalized medicine further fuel market growth in the region. Additionally, regulatory frameworks supporting the use of pharmacogenetic tests in clinical settings are driving the adoption of these technologies across North America.

Competitive Landscape and Key Players

The pharmacogenetic testing market is highly competitive, with key players such as Thermo Fisher Scientific, Illumina, Abbott Laboratories, and Qiagen dominating the space. These companies offer a range of testing platforms, reagents, and diagnostic solutions designed to improve genetic testing accuracy and efficiency.

Innovation in next-generation sequencing (NGS), microarray technology, and polymerase chain reaction (PCR) are key drivers shaping the market. Furthermore, strategic partnerships, collaborations with pharmaceutical companies, and the development of new genetic testing technologies are expected to enhance competition and drive further market expansion.

Recent Developments:

• Myriad Genetics, Inc. launched a new pharmacogenomic panel for oncology drug response testing, expanding its precision medicine portfolio.
• Thermo Fisher Scientific Inc. unveiled an advanced NGS-based platform tailored for pharmacogenetic applications in clinical research.
• 23andMe, Inc. partnered with a pharmaceutical company to explore genetic insights for drug development using pharmacogenomics.
• Illumina, Inc. announced a strategic collaboration to integrate genomic testing in healthcare systems, emphasizing pharmacogenetics.
• LabCorp introduced a new pharmacogenomic testing service for psychiatric medication management, enhancing personalized care.

List of Leading Companies:

• Myriad Genetics, Inc.
• 23andMe, Inc.
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• Laboratory Corporation of America Holdings (LabCorp)
• Quest Diagnostics Incorporated
• Invitae Corporation
• F. Hoffmann-La Roche Ltd.
• QIAGEN N.V.
• Color Genomics, Inc.
• Genomic Health, Inc.
• Agilent Technologies, Inc.
• Centogene AG
• Eurofins Scientific
• PacBio (Pacific Biosciences of California, Inc.)

Report Scope: